Cytosorbents (CTSO) Current Assets (2010 - 2026)

Cytosorbents' Current Assets history runs 17 years deep, the most recent figure standing at $17.8 million for Q1 2026.

• Quarterly Current Assets fell 30.13% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (down 30.13% YoY) and the FY2025 annual result came in at $20.6 million, down 4.49% from the prior year.
• Current Assets was $17.8 million for Q1 2026 at Cytosorbents, down from $20.6 million in the prior quarter.
• Across five years, Current Assets topped out at $55.9 million in Q1 2022 and bottomed at $16.6 million in Q3 2024.
• A 5-year average of $26.4 million and a median of $23.0 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets tumbled 55.49% — and 2025, when it gained 28.41%.
• Cytosorbents' Current Assets stood at $33.8 million in 2022, then slipped by 24.77% to $25.4 million in 2023, then slipped by 14.94% to $21.6 million in 2024, then dropped by 4.49% to $20.6 million in 2025, then slipped by 13.94% to $17.8 million in 2026.
• Business Quant data shows CTSO's Current Assets at $17.8 million in Q1 2026, $20.6 million in Q4 2025, and $21.3 million in Q3 2025.